Pai buy MDMA pills

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Pai buy MDMA pills

Official websites use. Share sensitive information only on official, secure websites. Methamphetamine is a stimulant drug. A strong form of the drug is illegally sold on the streets. A much weaker form of the drug is used to treat narcolepsy and attention deficit hyperactivity disorder ADHD. This weaker form is sold as a prescription. Medicines that are legally used to treat cold symptoms, such as decongestants, can be made into methamphetamines. This article focuses on the illegal street drug. The street drug is usually a white crystal-like powder, called 'crystal meth. A methamphetamine overdose may be acute sudden or chronic long-term. Injuries during illegal methamphetamine production or police raids include exposure to dangerous chemicals, as well as burns and explosions. All of these can cause serious, life threatening injuries and conditions. This is for information only and not for use in the treatment or management of an actual overdose. If you have an overdose, you should call your local emergency number such as or the local poison control center can be reached directly by calling the national toll-free Poison Help hotline from anywhere in the United States. Methamphetamine is a common, illegal, drug sold on the streets. It may be called meth, crystal meth, crank, speed, glass, tweak, chalk, Tina, or ice. A much weaker form of methamphetamine is sold as a prescription with the brand name Desoxyn. It is sometimes used to treat narcolepsy. Adderall, a brand name drug containing amphetamine, is used to treat ADHD. Methamphetamine most often causes a general feeling of wellness euphoria that is most often called a 'rush. If you take a large amount of the drug, you will be at higher risk for more dangerous side effects, including:. The length of time methamphetamines stay active can be much longer than for cocaine and other stimulants. Some paranoid delusions can last for 15 hours. If you believe someone has taken methamphetamine and they are having bad symptoms, get them medical help right away. Take extreme caution around them, especially if they appear to be extremely excited or paranoid. If they are having a seizure, gently hold the back of their head to prevent injury. If possible, turn their head or body to the side in case they vomit. DO NOT try to stop their arms and legs from shaking, or put anything in their mouth. If the patient is actively having a seizure, becoming violent, or having difficulty breathing, do not delay. Call your local emergency number such as Your local poison control center can be reached directly by calling the national toll-free Poison Help hotline from anywhere in the United States. This national hotline number will let you talk to experts in poisoning. They will give you further instructions. This is a free and confidential service. All local poison control centers in the United States use this national number. You should call if you have any questions about poisoning or poison prevention. It does NOT need to be an emergency. You can call for any reason, 24 hours a day, 7 days a week. The health care provider will measure and monitor the person's vital signs, including temperature, pulse, breathing rate, and blood pressure. Symptoms will be treated as appropriate. The person may receive:. How well a person does depends on the amount of drug they took and how quickly they were treated. The faster a person gets medical help, the better the chance for recovery. Psychosis and paranoia may last up to 1 year, even with aggressive medical treatment. Memory loss and difficulty sleeping may be permanent. Skin changes and tooth loss are permanent unless the person has cosmetic surgery or dentistry to correct the problems. Further disability may occur if the person had a heart attack or a stroke. These can happen if the drug caused very high blood pressure and body temperatures. Infections and other complications in organs such as the heart, brain, kidneys, liver, and spine, may occur as a result of injection. There may be permanent damage to the organs even if the person receives treatment. The antibiotics used to treat these infections may also result in complications. The long-term outlook depends on what organs are affected. Permanent damage may occur, which may cause:. Intoxication - amphetamines; Intoxication - uppers; Amphetamine intoxication; Uppers overdose; Overdose - methamphetamine; Crank overdose; Meth overdose; Crystal meth overdose; Speed overdose; Ice overdose. Aronson JK. In: Aronson JK, ed. Meyler's Side Effects of Drugs. Waltham, MA: Elsevier B. Brust JCM. Effects of drug abuse on the nervous system. Bradley and Daroff's Neurology in Clinical Practice. Philadelphia, PA: Elsevier; chap Jamshidi N, Dawson AH. Textbook of Adult Emergency Medicine. Also reviewed by David C. Editorial team. Methamphetamine overdose. An acute methamphetamine overdose occurs when someone takes this drug by accident or on purpose and has side effects. These side effects can be life threatening. A chronic methamphetamine overdose refers to the health effects in someone who uses the drug on a regular basis. Poisonous Ingredient. If you take a large amount of the drug, you will be at higher risk for more dangerous side effects, including: Agitation Chest pain Coma or unresponsiveness in extreme cases Heart attack Irregular or stopped heartbeat Difficulty breathing Very high body temperature Kidney damage and possibly kidney failure Paranoia Seizures Severe stomach pain Stroke Long-term use of methamphetamine can lead to significant psychological problems, including: Delusions Delusional behavior Extreme paranoia Major mood swings Insomnia severe inability to sleep Other symptoms may include: Missing and rotted teeth called 'meth mouth' Repeated infections Severe weight loss Skin sores abscesses or boils The length of time methamphetamines stay active can be much longer than for cocaine and other stimulants. Before Calling Emergency. Before you call for emergency help, have this information ready, if possible: Person's approximate age and weight. How much of the drug was taken? How was the drug taken? For example, was it smoked or snorted? How long has it been since the person took the drug? What to Expect at the Emergency Room. The person may receive: Activated charcoal and laxative, if the drug was recently taken by mouth. Blood and urine tests. Breathing support, including oxygen. If needed, the person may be placed on a breathing machine with a tube through the mouth into the throat. Chest x-ray if the person had vomiting or abnormal breathing. CT computerized tomography scan of the head, if head injury is suspected. ECG electrocardiogram, or heart tracing. Intravenous fluids through a vein medicines to treat symptoms such as pain, anxiety, agitation, nausea, seizures, and high blood pressure. Poison and drug toxicology screening. Other medicines or treatments for heart, brain, muscle, and kidney complications. Outlook Prognosis. Permanent damage may occur, which may cause: Seizures, stroke, and paralysis Chronic anxiety and psychosis severe mental disorders Decreased mental functioning Heart problems Kidney failure that requires dialysis kidney machine Destruction of muscles, which can lead to amputation A large methamphetamine overdose can cause death. Alternative Names. Learn how to cite this page. Related MedlinePlus Health Topics.

Methamphetamine overdose

Pai buy MDMA pills

Official websites use. Share sensitive information only on official, secure websites. This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Findings demonstrate a high prevalence of chronic pain in this sample of people with severe PTSD and that chronic pain scores among medium and high pain subgroups were significantly lower following MDMA-AT. For instance, pilot studies have explored the potential for MDMA-AT in end of life anxiety 6 , social anxiety in autistic adults 7 , and alcohol use disorder 8 , and exploratory analysis has generated preliminary data for eating disorders 9 , Chronic pain, defined as consistent pain for at least 3 months 14 , is a leading cause of disability and is associated with a reduced life expectancy Innovative approaches to managing chronic pain that reduce long term reliance on pharmaceutical interventions are needed. PTSD is a complex, difficult to treat, stress-related psychiatric condition with somatization symptoms that has a profound impact on individuals and society and for which novel treatments are needed 1 , Chronic pain and PTSD are also frequently comorbid; two systematic reviews found prevalence rates of PTSD in clinical pain populations to range from Both conditions are independently associated with OUD, yet when comorbid are associated with even higher odds of OUD than either condition alone Those with comorbid pain and PTSD also experience greater pain, PTSD symptoms, depression, anxiety, and disability than those with only one of these conditions 27 , Chronic pain and PTSD have been described as reciprocally interdependent conditions, with similar maintenance mechanisms such as fear, avoidance, and catastrophizing 29 , It has even been suggested that chronic pain might indeed be interpreted as a version of PTSD The Mutual Maintenance Model suggests PTSD and chronic pain exacerbate one another through biases of attention and cognition that create heightened expectations, overestimations, and selective and negative interpretations of both pain-evoking and fear-evoking stimuli. Pain may also serve as a traumatic cue, leading to intrusive PTSD symptoms, and vice versa The Shared Vulnerability Model posits that anxiety sensitivity and genetic predispositions related to the stress response increase the likelihood for certain individuals to develop both conditions This notion is further supported by evidence suggesting efficacy for psychotherapeutic approaches in chronic pain 34 and the established importance of biopsychosocial interventions for chronic pain, with MDMA-AT being at once a biological and psychological treatment, combining the pharmacological effects of MDMA with psychotherapy. The researchers designed the study to model the structure of planned Phase 3 trials, and to prepare and supervise sites planning to be part of the Phase 3 studies. Details and primary outcomes of the study have been previously described 1. Participants could not have a diagnosis of substance use disorder within 60 days of screening, and psychiatric medications were tapered and discontinued prior to commencing study drug sessions. Participants were allowed to continue concomitant analgesic medications including non-steroidal anti-inflammatory drugs NSAIDS , acetaminophen, gabapentin, and opiates limited to hydrocodone, morphine and codeine. Participants taking other opiates at enrollment were cross-tapered to an allowable opiate during the preparatory period. Concomitant use of cannabis was prohibited from enrollment to study termination. MDMA administration occurred on three occasions and each session was 8-h in duration in the presence of the co-therapy dyad. According to the flexible dosing schedule, in the first study drug session, all participants received an initial dose of 80 mg MDMA HCl, followed 1. All participants followed this dose escalation. The supplemental dose was withheld by the investigator in two instances due to tachycardia and elevated blood pressure following the initial dose, though neither required further medical intervention The primary outcome for the present analysis was chronic pain, as measured by the CPGS questionnaire, which was administered twice, at Preparatory Session 3 prior to the first MDMA session , and at study termination which occurred 10—14 weeks after the final MDMA session. Participants were asked to base their responses at study termination on the period since the end of treatment. Secondarily, we looked for associations between chronic pain, childhood adversity and PTSD severity at baseline. The CPGS questionnaire is a 7-item self-report instrument that measures two dimensions of overall pain severity: pain intensity and pain-related disability, and is valid and reliable for measuring change in severity of chronic pain over time Data encompass current pain, as well as past 6 months pain and pain-related disability and is suitable for use in all chronic pain conditions. Pain intensity and disability score subscales are combined with disability points score to assign a chronic pain severity grade 0-IV ; individual subscales as well as overall severity grade have demonstrated validity and reliability 38 for definitions of CPGS severity grade 0—IV , see Table 1. Demographic variables included age, sex, and ethnicity white vs. Severity grade is classified using the two subscales included in the present analysis Pain intensity 0—, disability score 0— plus a disability points value number of disability days in the past 6 months converted to a 0—3-point scale plus disability score 0— converted to a 0—3-point scale. Statistical analyses were performed using R version 4. We hypothesized that only participants reporting medium or high within-sample chronic pain at baseline would experience significant improvement post-treatment, therefore we repeated the same analysis for each CPGS cluster. Bivariate linear and ordinal regression reveal no strong associations between pre-treatment CPG subscale values and pre-treatment CAPS-5 total severity, ACE score, or demographic variables. In bivariate t -testing and ANOVA, among those in the highest pain cluster mean CPGS values each of pain intensity, disability score, and severity grade were significantly reduced post-intervention vs. The present study found a high prevalence of pain among this sample of individuals with PTSD, in keeping with other published data demonstrating high rates of comorbid pain and PTSD Significant reductions in pain and pain-related disability among participants in the highest pain cluster may be due to higher baseline pain values allowing greater margin for improvement; there may also be a mechanism related to an amygdala-based threat response to higher levels of pain being positively impacted by MDMA-AT, since overlapping brain areas have been shown to be active in both pain related threat perception, and anxiety and fear-based threat perception as typified by PTSD Interestingly, among this sample baseline pain severity and PTSD severity were not positively correlated Table 3. We speculate that differences in pain perception among individuals with PTSD symptoms may account for this finding; for example, high PTSD severity may distract from pain symptomatology, and vice versa, but this warrants further investigation. Previous research has demonstrated a unique and paradoxical pain perception pattern hypo-responsiveness and hyper-sensitivity in experimental and chronic pain among people with PTSD: PTSD-related dissociation was associated with higher pain threshold, whereas supra-threshold pain stimulus ratings were higher in those with PTSD in comparison to controls. Pain hyper-responsiveness was positively associated with anxiety sensitivity, but negatively correlated with dissociation levels Anxiety and dissociation are intercorrelated in PTSD 41 yet their relationship to pain perception among people with PTSD has not been systematically studied and warrants further investigation. Chronic pain is an international public health emergency for which new treatments are desperately needed 42 , While chronic pain is frequently comorbid with PTSD, few studies have examined treatments designed to effectively address both conditions concurrently 40 , yet when outcomes are assessed related to psychological interventions for both disorders in individual studies, moderate effects for PTSD and small effects for pain emerge, suggesting transdiagnostic effects International best practice recommendations involve understanding and addressing chronic pain within a biopsychosocial model, with personalized multidisciplinary treatment approaches that include both physical and psychological interventions 42 , History of psychological, emotional, sexual, or physical abuse or a combination of these predispose to nociplastic pain These conditions tend to respond poorly to physical treatment medication or procedural interventions , and more readily to non-pharmacological approaches, such as educational, behavioral and psychotherapy interventions MDMA is a psychoactive compound that promotes serotonin release, and may exert therapeutic effects by enhancing fear memory extinction 47 , promoting greater self-compassion 48 , reducing self-criticism 48 , reducing PTSD-related shame and anger 49 and causing acute prosocial and interpersonal effects that support the quality of the therapeutic alliance in psychotherapy MDMA promotes oxytocin release, which helps increase interpersonal focus, feelings of interpersonal trust and social affiliation 51 — 53 , and has been shown to reduce pain associated with social rejection MDMA-AT has been associated with changes in personality persisting at two-month follow-up, notably increased personality trait Openness and reduction in Neuroticism Given the high comorbidity of PTSD and chronic pain reflected in the present analysis, and the growing literature suggesting shared mechanisms both predisposing to and maintaining both conditions, it is conceivable that some of these proposed mechanisms explaining the efficacy of MDMA-AT for PTSD may be relevant for treating chronic pain. In particular, MDMA-AT effects related to enhanced fear extinction and approaching rather than avoiding negatively charged content may be relevant to fear and avoidance phenomena that are known to intensify and perpetuate chronic pain Self-compassion, enhanced through MDMA, has also been linked with improved pain outcomes Treatment with an existential focus may play an important role in chronic pain recovery 42 , 58 particularly when combined with other psychological and pharmacological approaches 40 and has been shown to be effective in decreasing pain-related disability MDMA-related improvements in intrapersonal attitudes including reduced self-criticism may impart benefit to chronic pain-associated existential challenges to related to identity, social roles, meaning and purpose, which are relevant yet underrepresented areas of treatment focus for chronic pain Interpersonal effects that enhance therapeutic alliance may also be of relevance since psychological interventions for chronic pain require a strong therapeutic relationship to maximize benefit Additionally, MDMA-enhanced perception of social connection and support may target chronic pain-related social isolation, a factor that exacerbates pain symptomatology, and when reduced, is associated with improvements in emotional and physical functioning among chronic pain patients The potential for MDMA-AT to promote change in personality including reduced trait Neuroticism may also be of relevance, since neuroticism predicts poor adjustment to chronic pain Our data demonstrate a high median ACE score among this sample 4; IQR 3—7 and are consistent with previous research in the intersecting fields of chronic pain and trauma, that indicate an association with adverse childhood experiences ACE 13 , Stress response psychobiology is of particular relevance to this discussion. The capacity to tolerate increased levels of stress and to recover quickly, known as resilience, relies upon optimal environmental conditions whereby interacting psychobiological systems can develop ideal responses, and healthy attachment relationships are of particular importance The potential of MDMA to re-open critical period neuroplasticity related to social reward learning, combined with interpersonal effects such as enhanced empathy and trust, may create optimal conditions within the MDMA-AT therapeutic relationship to improve resilience and thus create more favorable conditions for recovering from chronic pain and other chronic conditions that are negatively impacted by stress. K-means clustering provided a simple and efficient method to define groups according to pre-treatment CPGS values representing high, medium, and low within-sample pain values, which allowed for analysis using regression, t -testing and ANOVA for the whole sample and then separately for each of these stable clusters. Analysis was not conducted according to a hierarchical testing strategy, introducing the possibility for Type 1 error. Despite these limitations, participants in this sample were not subject to expectation bias regarding any positive impact of MDMA-AT on pain, since participants were recruited to the original study for experimental treatment of PTSD, whereas CPGS was administered and collected as exploratory data only. These data encourage further research with a larger sample in randomized, controlled trials in which the intervention is specifically investigated as a treatment for chronic pain. Future studies could address exposure-response analyses on change in chronic pain. While the CPGS is a valid and reliable instrument, recall bias may limit accuracy of self-report responses. Therefore, while participants were aware the point scale asked for a rating of severity of pain interference with daily activities, they might have interpreted extreme change as still allowing for minimal activity, rather than absolute inability to carry on any activities. This could theoretically lead to false elevation of baseline and post-intervention disability score , which could likewise falsely elevate total severity score. Associations between MDMA-AT and chronic pain may be influenced by confounding variables not examined in the present study, such as concurrent analgesic medications. Furthermore, participants in study MP16 were not selected for experiencing chronic pain, rather they were selected for having PTSD symptoms for at least 6 months, therefore some participants may have completed the questionnaire in reference to pain experienced for a shorter period. This limits generalizability of these exploratory data to true chronic pain conditions that are not comorbid with PTSD. Within study population and within cluster distribution of pain by etiology could lead to further information and enhance future research protocols investigating MDMA-AT for chronic pain that include a mixed sample. This study included predominantly white participants, which limits the generalizability of the findings to other populations. Not all people are affected by chronic pain equally; most data indicate higher prevalence in racialized and marginalized populations including African American and Indigenous people, women, and individuals from lower socioeconomic backgrounds Further research should aim to increase diversity among research participants, as well as consider how chronic pain is experienced across the lifespan and across cultures. These findings demonstrate a high prevalence of pain in this sample of participants with severe PTSD, and that pain intensity, disability, and a composite pain severity index grade among those with the highest pain were significantly lower following MDMA-AT. While these data are limited and primarily hypothesis generating, they suggest that MDMA-AT may be associated with reductions in pain and pain-related disability among individuals with PTSD. Restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. All requests for raw and analyzed data are promptly reviewed by MAPS PBC to verify if the request is subject to any confidentiality obligations. Patient-related data not included in this publication were generated as part of clinical trials and may be subject to patient confidentiality. Any data that can be shared may be released via a data use agreement. Participants provided their written and informed consent for participation in MP BY-K: substantial contributions to the conception and design of study MP DC and EA: data analysis, plan conception, and design. DC: initial draft manuscript preparation. All authors contributed to the article and approved the submitted version. Ilsa Jerome Ph. We express appreciation to all the participants, investigators, and research staff who made this work possible. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Front Psychiatry. Find articles by Devon Christie. Find articles by Berra Yazar-Klosinski. Find articles by Ekaterina Nosova. Find articles by Pam Kryskow. Will Siu 5 MD Inc. Find articles by Will Siu. Find articles by Danielle Lessor. Find articles by Elena Argento. Received May 9; Accepted Oct 14; Collection date Open in a new tab. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel. Bivariate ordinal regression estimate.

Pai buy MDMA pills